Explore 10 human studies.
Research has examined glutathione stores, liver markers and skin appearance. Some findings are encouraging; others are mixed or show no benefit.
These studies used different products, doses and populations. None tested Vyera. This is a selected research library, not a systematic review.
Liver research
Irie et al., 2016 · Liver-marker pilot · 3 months
Who and what: 15 people with biopsy-confirmed fatty liver: 5 with simple fatty liver and 10 with non-alcoholic steatohepatitis (NASH). Everyone took oral reduced glutathione, 300 mg daily, for 3 months. There was no control group.
Finding: the liver enzyme ALT and an oxidative-damage marker, 8-OHdG, decreased significantly in the NASH subgroup.
Limits: a small, uncontrolled study with a subgroup finding. It does not show reversal of fatty liver, prevention of progression or an effect from Vyera.
Read Irie et al. on PubMed ↗
Honda et al., 2017 · Liver-marker pilot · 4 months
Who and what: 34 people with non-alcoholic fatty liver disease enrolled. After 3 months of diet-and-exercise guidance, 32 began oral glutathione, 300 mg daily, for 4 months; 29 completed the study. This was an open-label study without a control group.
Finding: ALT decreased. The study also reported improvements in triglycerides, non-esterified fatty acids and ferritin. A liver-fat measurement improved only in the subgroup whose ALT responded.
Limits: lifestyle changes and the lack of a control group make cause and effect uncertain. Overall liver-fat and liver-stiffness measurements did not improve significantly. This was not a Vyera trial.
Read Honda et al. on PubMed ↗
Skin appearance
Arjinpathana & Asawanonda, 2012 · Controlled skin trial · 4 weeks
Who and what: 60 healthy medical students enrolled and completed this randomized, double-blind trial. They received oral glutathione capsules, 500 mg daily in two doses, or placebo for 4 weeks.
Finding: pigmentation measurements decreased more than with placebo at 2 of 6 sites: the right side of the face and the sun-exposed left forearm.
Limits: a short study with site-specific findings. It does not establish a general visible glow, long-term effects or results from Vyera.
Read Arjinpathana & Asawanonda on PubMed ↗
Handog et al., 2016 · Skin lozenge pilot · 8 weeks
Who and what: 30 Filipino women with Fitzpatrick skin types IV or V received a glutathione lozenge daily for 8 weeks. This was an open-label, single-arm study. The accessible primary abstract does not report the dose or a separate completion count.
Finding: melanin measurements decreased from baseline, with changes reported from two weeks.
Limits: without a control group, the study cannot establish a treatment effect or a two-week results promise. It tested a lozenge, not Vyera, and was funded by Brady Pharma.
Read Handog et al. on PubMed ↗
Weschawalit et al., 2017 · Controlled skin trial · 12 weeks
Who and what: 60 women enrolled and 57 completed a randomized, double-blind, placebo-controlled trial. Participants took reduced or oxidized oral glutathione, 250 mg daily, or placebo for 12 weeks.
Finding: some site-specific or subgroup measurements improved, but the overall pigmentation comparisons were not significant. A significant wrinkle finding concerned a sun-protected arm.
Limits: mixed findings in a small, specific population. An arm measurement does not establish facial anti-ageing benefits, and this trial did not test Vyera.
Read Weschawalit et al. on PubMed ↗
Glutathione stores and formulation
Richie et al., 2015 · Controlled oral trial · 6 months
Who and what: 54 healthy adults took part in a randomized, double-blind, placebo-controlled trial of non-liposomal oral glutathione at 250 or 1,000 mg daily for 6 months.
Finding: glutathione stores increased in several measured body compartments. In the higher-dose group, red-blood-cell, plasma and lymphocyte levels rose about 30–35% from baseline at six months.
Limits: laboratory changes do not establish liver-disease or skin benefits. This study tested another preparation and does not prove liposomal superiority or Vyera's effectiveness.
Read Richie et al. on PubMed ↗
Sinha et al., 2018 · Liposomal pilot · 4 weeks
Who and what: 12 healthy adults aged 51–72 took Tri-Fortify Orange liposomal glutathione, 500 or 1,000 mg daily, for 4 weeks. They were assigned to two dose groups, with no placebo group.
Finding: several blood glutathione measurements increased, alongside encouraging changes in oxidative-stress and immune-cell markers.
Limits: a small, uncontrolled pilot funded by the tested product's manufacturer, Researched Nutritionals. Immune-cell markers do not prove fewer infections. The formulation was not Vyera.
Read Sinha et al. on PubMed ↗
Schmitt et al., 2015 · Sublingual crossover · 21-day periods
Who and what: 20 people with metabolic syndrome received three preparations in randomized order, each for 21 days with 14-day washouts: Sublinthion sublingual glutathione, 450 mg daily; oral glutathione capsules, 450 mg daily; and N-acetylcysteine (NAC), 200 mg daily.
Finding: the sublingual product improved plasma glutathione measurements and the reduced-to-oxidized glutathione ratio relative to oral glutathione. Plasma vitamin E also increased.
Limits: a small comparison of specific formulations. It does not establish clinical benefits or show that any liquid dropper product bypasses digestion or absorbs within seconds.
Read Schmitt et al. on PubMed ↗
Prasad et al., 2026 · Liposomal absorption comparison · 24 hours
Who and what: 12 healthy adults, 6 per group, received a single 1 g dose of LipoDuo liposomal glutathione or plain glutathione in an open-label, parallel-group study. Plasma levels were measured over 24 hours.
Finding: the tested liposomal preparation produced a substantially higher peak plasma glutathione concentration.
Limits: a small absorption study with authors affiliated with the product developer. It does not establish clinical skin or liver benefits, or better absorption from Vyera. The paper's separate cell-culture wound-healing findings are not human clinical results.
Read Prasad et al. on PubMed ↗
Allen & Bradley, 2011 · Controlled oral trial · 4 weeks
Who and what: 40 adults without acute or chronic disease enrolled and 39 completed a randomized, double-blind, placebo-controlled trial. They took oral glutathione capsules, 500 mg twice daily (1,000 mg daily), or placebo for 4 weeks.
Finding: there was no significant improvement over placebo in glutathione status or the measured oxidative-stress markers.
Limits: a short trial of a different formulation. Its null result is part of the evidence and helps explain why findings from selected positive studies cannot settle overall effectiveness.
Read Allen & Bradley on PubMed ↗
Study doses describe the research; they are not directions for using Vyera. Follow your product label. Changes in laboratory or skin measurements do not establish a noticeable benefit or a guaranteed result from this product. These ten entries exclude studies of glutathione combined with other active ingredients.
